General Information of the Drug (ID: M6APDG04054)
Name
AMXI 5001
Status
Phase 1/2
TTD Drug ID
D8TE4F
Target Gene(s) and Their Upstream m6A Regulator, Together with the Effect of Target Gene(s) in Drug Response
The target genes involved in drug-target interaction (such as drug-metabolizing enzymes, drug transporters and therapeutic targets) and drug-mediated cell death signaling (including modulating DNA damage and repair capacity, escaping from drug-induced apoptosis, autophagy, cellular metabolic reprogramming, oncogenic bypass signaling, cell microenvironment, cell stemness, etc.) could be regulated by m6A regulator(s) and affected their corresponding drug response. You can browse detailed information on drug-related target gene(s) mediated by m6A regulators.
Poly [ADP-ribose] polymerase 1 (PARP1)
Methyltransferase-like 3 (METTL3)
In total 1 mechanisms lead to this potential drug response
Response Summary Poly [ADP-ribose] polymerase 1 (PARP1) is a therapeutic target for AMXI 5001. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of AMXI 5001 through regulating the expression of Poly [ADP-ribose] polymerase 1 (PARP1). [1], [2]
YTH domain-containing family protein 1 (YTHDF1)
In total 1 mechanisms lead to this potential drug response
Response Summary Poly [ADP-ribose] polymerase 1 (PARP1) is a therapeutic target for AMXI 5001. The YTH domain-containing family protein 1 (YTHDF1) has potential in affecting the response of AMXI 5001 through regulating the expression of Poly [ADP-ribose] polymerase 1 (PARP1). [1], [2]
References
Ref 1 METTL3 promotes oxaliplatin resistance of gastric cancer CD133+?stem cells by promoting PARP1 mRNA stability. Cell Mol Life Sci. 2022 Feb 18;79(3):135. doi: 10.1007/s00018-022-04129-0.
Ref 2 PARP inhibitors as antitumor agents: a patent update (2013-2015). Expert Opin Ther Pat. 2017 Mar;27(3):363-382. doi: 10.1080/13543776.2017.1259413. Epub 2016 Nov 21.